T_Ortega_Lifts wrote:BPC-157 and Ipamorelin specifically are actually one of the lower-risk combos for same-syringe drawing since their pH ranges aren't wildly incompatible.
This is an important point and I want to reinforce and expand on it, because I think it captures the most valuable lesson in this thread for newer researchers.
T_Ortega is correct that BPC-157 and Ipamorelin occupy relatively compatible stability ranges, which is part of why OP likely did not observe dramatic degradation or unusual physiological effects. BPC-157 in its acetate salt form demonstrates stability across a reasonably broad pH range, and Ipamorelin, as a pentapeptide GH secretagogue, is similarly not among the more finicky compounds in terms of solvent compatibility. So yes, OP got fortunate with the choice of compounds, even if the methodology was improvised.
To build on what gainz_peptide_bro and T_Ortega already said about the bacteriostatic versus sterile water issue: this deserves careful attention because the pharmacokinetic implications are not trivial. Bacteriostatic water contains approximately 0.9% benzyl alcohol, which serves as an antimicrobial preservative and meaningfully extends the viable storage window of a reconstituted peptide. When you combine a solution reconstituted in bacteriostatic water with one reconstituted in sterile water, you are reducing the effective benzyl alcohol concentration in your combined solution. Depending on the volumetric ratio, this could represent a significant reduction in preservative capacity. For anyone planning to store reconstituted peptides beyond twenty-four to forty-eight hours, this matters considerably.
IronGutPeptideBro wrote:that uniform haze she described is not automatically a sign everything is ruined
Agreed, and the distinction between uniform turbidity and visible particulate matter is well established in pharmaceutical stability literature. Particulate contamination raises legitimate concerns about aggregation, precipitation, or microbial contamination, all of which are disqualifying. A uniform, transient haze attributable to temperature differential or concentration effects is a different phenomenon entirely, and the reflexive disposal response, while understandable, is not always analytically justified.
That said, I want to add one clarifying point for OP and any other newer researchers reading this thread:
the practical problem is that without HPLC or similar analytical instrumentation, none of us can actually verify peptide integrity after an unanticipated mixing event. We are reasoning from appearance, which is a necessary but insufficient proxy. This is precisely why the procedural discipline T_Ortega outlined, separate vials for reconstitution, syringe combination only at draw time if at all, matters so much. You are not just protecting the peptides, you are preserving your ability to reason about what you actually administered.
OP, your sleep improvement is consistent with what the published literature suggests regarding Ipamorelin's effects on GH pulsatility and downstream sleep architecture. Mehta et al. and the earlier Bowers work on GH secretagogues are worth reviewing if you want a mechanistic foundation for what you are likely experiencing. The outcome here sounds positive, and the lesson you took away, separate injections going forward, is the correct one.